NICE appraisal for BMS kidney cancer immunotherapy combination

Pharma Times

5 April 2019 - NICE has issued a Final Appraisal Determination endorsing NHS use of an Opdivo (nivolumab) and Yervoy (ipilimumab) combination in renal cell carcinoma.

The news means around 1,700 people with kidney cancer in England will have a new treatment option, and signifies an important landmark in the treatment landscape, representing the first approval of an immuno-oncology combination therapy for first-line patients with this type of cancer in England.

American drug-maker Bristol-Myers Squibb announced that the immunotherapy combination is to be immediately available via the Cancer Drugs Fund, based on data from a Phase III head-to-head study, which was stopped early due to an overall survival efficacy benefit versus sunitinib, a current standard of care.

Read Pharma Times article

Michael Wonder

Posted by:

Michael Wonder